BR100 Increased By (0.25%)
BR30 Increased By (1.07%)
KSE100 Increased By (0.41%)
KSE30 Increased By (0.37%)
BECO 5.48 Decreased By ▼ -0.01 (-0.18%)
BML 55.90 Decreased By ▼ -0.86 (-1.52%)
BOP 35.20 Increased By ▲ 0.08 (0.23%)
CNERGY 8.20 Increased By ▲ 0.05 (0.61%)
DCL 11.58 Increased By ▲ 0.07 (0.61%)
FCCL 57.20 Increased By ▲ 0.45 (0.79%)
FCSC 5.18 Increased By ▲ 0.03 (0.58%)
FFL 18.11 Increased By ▲ 0.23 (1.29%)
FNEL 1.27 Increased By ▲ 0.02 (1.6%)
HUMNL 11.20 Increased By ▲ 0.08 (0.72%)
KEL 8.63 Increased By ▲ 0.21 (2.49%)
KOSM 6.63 Increased By ▲ 0.05 (0.76%)
MLCF 105.00 Increased By ▲ 1.70 (1.65%)
NBP 200.45 Increased By ▲ 0.27 (0.13%)
PACE 11.29 No Change ▼ 0.00 (0%)
PAEL 44.42 Increased By ▲ 0.95 (2.19%)
PIAHCLA 28.00 Increased By ▲ 0.51 (1.86%)
PIBTL 18.85 Increased By ▲ 1.15 (6.5%)
PPL 245.61 Increased By ▲ 1.29 (0.53%)
PRL 35.47 Increased By ▲ 0.04 (0.11%)
PTC 65.40 Increased By ▲ 0.05 (0.08%)
SEARL 94.00 Increased By ▲ 0.68 (0.73%)
SSGC 32.47 Decreased By ▼ -0.47 (-1.43%)
TELE 8.90 Decreased By ▼ -0.01 (-0.11%)
THCCL 66.90 Increased By ▲ 0.18 (0.27%)
TPLP 10.87 Increased By ▲ 0.04 (0.37%)
TREET 25.35 Increased By ▲ 0.23 (0.92%)
TRG 64.69 Decreased By ▼ -0.21 (-0.32%)
WAVES 10.91 Decreased By ▼ -0.02 (-0.18%)
WTL 1.26 Increased By ▲ 0.01 (0.8%)
World

Oxford says COVID-19 vaccine 76pc effective for 3 months after one shot

  • AstraZeneca has welcomed the move, saying flexibility to extend the time between doses is the best strategy for the shot.
Published February 2, 2021 Updated February 2, 2021 11:36pm
By

LONDON: The COVID-19 vaccine developed by Oxford University and AstraZeneca has 76pc efficacy against symptomatic infection for three months after a single dose, with greater effectiveness when a second is given later, a study showed on Tuesday.

Oxford University said the findings of the pre-print paper, which had not been peer-reviewed, supported Britain's decision to extend the interval between initial and booster doses of the shot to 12 weeks.

Britain has decided to give as many people as possible some protection by lengthening the amount of time between initial shots and booster shots of COVID-19 vaccines.

AstraZeneca has welcomed the move, saying flexibility to extend the time between doses is the best strategy for the shot.

The results, gathered from trials in Britain, Brazil and South Africa, indicated some protection was given after one shot and that immune responses were boosted with a longer interval to the second dose among participants aged 18 to 55 years.

"Vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 post vaccination was 76pc, and modelled analysis indicated that protection did not wane during this initial 3 month period," Oxford academics said.

The paper said that vaccine efficacy was 82.4pc with 12 or more weeks to the second dose, compared to 54.9pc for those where the booster was given under 6 weeks after the first dose.

Comments

Comments are closed for this article.